{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:32:24Z","timestamp":1794846744751,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12951-018-0402-x","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T04:12:16Z","timestamp":1538712736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine"],"prefix":"10.1186","volume":"16","author":[{"given":"Jieping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-8424","authenticated-orcid":false,"given":"Hongwu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"issue":"9","key":"402_CR1","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S1470-2045(14)70008-7","volume":"15","author":"SC Meyer","year":"2014","unstructured":"Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15(9):e382\u201394.","journal-title":"Lancet Oncol"},{"issue":"2","key":"402_CR2","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1038\/bcj.2017.2","volume":"7","author":"SS Hoseini","year":"2017","unstructured":"Hoseini SS, Cheung NK. Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J. 2017;7(2):e522.","journal-title":"Blood Cancer J"},{"issue":"4","key":"402_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"12","key":"402_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"9","key":"402_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"402_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-017-0519-7","volume":"10","author":"M Fan","year":"2017","unstructured":"Fan M, Li M, Gao L, et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. J Hematol Oncol. 2017;10(1):151.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"402_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12967-017-1281-x","volume":"15","author":"SH Lim","year":"2017","unstructured":"Lim SH, Dubielecka PM, Raghunathan VM. Molecular targeting in acute myeloid leukemia. J Transl Med. 2017;15(1):183.","journal-title":"J Transl Med"},{"key":"402_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ejmech.2018.06.010","volume":"155","author":"Y Zhi","year":"2018","unstructured":"Zhi Y, Li B, Yao C, et al. Discovery of the selective and efficacious inhibitors of FLT3 mutations. Eur J Med Chem. 2018;155:303\u201315.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"402_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(18)30335-8","volume":"19","author":"EM Stein","year":"2018","unstructured":"Stein EM. FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia. Lancet Oncol. 2018;19(7):849\u201350.","journal-title":"Lancet Oncol"},{"issue":"9","key":"402_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1535-7163.MCT-17-0298","volume":"17","author":"R Wang","year":"2018","unstructured":"Wang R, Li Y, Gong P, Gabrilove J, Waxman S, Jing Y. Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells. Mol Cancer Ther. 2018;17(9):1871\u201380.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"402_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1208\/s12249-010-9520-y","volume":"11","author":"SK Battu","year":"2010","unstructured":"Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S. Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech. 2010;11(3):1466\u201375.","journal-title":"AAPS PharmSciTech"},{"key":"402_CR12","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.2147\/IJN.S144615","volume":"12","author":"J Yin","year":"2017","unstructured":"Yin J, Hou Y, Yin Y, Song X. Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. Int J Nanomed. 2017;12:8671\u201380.","journal-title":"Int J Nanomed"},{"key":"402_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ejphar.2014.06.025","volume":"740","author":"P Jabbarzadeh Kaboli","year":"2014","unstructured":"Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling KH. Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol. 2014;740:584\u201395.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"402_CR14","doi-asserted-by":"publisher","first-page":"12349","DOI":"10.3390\/molecules190812349","volume":"19","author":"LM Ortiz","year":"2014","unstructured":"Ortiz LM, Lombardi P, Tillhon M, Scovassi AI. Berberine, an epiphany against cancer. Molecules. 2014;19(8):12349\u201367.","journal-title":"Molecules"},{"issue":"12","key":"402_CR15","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.bmcl.2016.04.070","volume":"26","author":"SQ Wen","year":"2016","unstructured":"Wen SQ, Jeyakkumar P, Avula SR, Zhang L, Zhou CH. Discovery of novel berberine imidazoles as safe antimicrobial agents by down regulating ROS generation. Bioorg Med Chem Lett. 2016;26(12):2768\u201373.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"402_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.phrs.2007.06.003","volume":"56","author":"CH Lee","year":"2007","unstructured":"Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res. 2007;56(3):193\u2013201.","journal-title":"Pharmacol Res"},{"issue":"5","key":"402_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.pharep.2015.03.002","volume":"67","author":"T Ahmed","year":"2015","unstructured":"Ahmed T, Gilani AU, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. Berberine and neurodegeneration: a review of literature. Pharmacol Rep. 2015;67(5):970\u20139.","journal-title":"Pharmacol Rep"},{"issue":"7","key":"402_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1211\/jpp.61.07.0001","volume":"61","author":"M Ye","year":"2009","unstructured":"Ye M, Fu S, Pi R, He F. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol. 2009;61(7):831\u20137.","journal-title":"J Pharm Pharmacol"},{"key":"402_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/1472-6882-13-218","volume":"13","author":"AE Abd El-Wahab","year":"2013","unstructured":"Abd El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med. 2013;13:218.","journal-title":"BMC Complement Altern Med"},{"issue":"1A","key":"402_CR20","first-page":"227","volume":"26","author":"CC Lin","year":"2006","unstructured":"Lin CC, Kao ST, Chen GW, Ho HC, Chung JG. Apoptosis of human leukemia HL-60 cells and murine leukemia WEHI-3 cells induced by berberine through the activation of caspase-3. Anticancer Res. 2006;26(1A):227\u201342.","journal-title":"Anticancer Res"},{"issue":"2A","key":"402_CR21","first-page":"1097","volume":"26","author":"C-C Lin","year":"2006","unstructured":"Lin C-C, Lin S-Y, Chung J-G, Lin J-P, Chen G-W, Kao S-T. Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2\/M-phase of the cell cycle. Anticancer Res. 2006;26(2A):1097\u2013104.","journal-title":"Anticancer Res"},{"issue":"7","key":"402_CR22","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1142\/S0192415X17500811","volume":"45","author":"S Okubo","year":"2017","unstructured":"Okubo S, Uto T, Goto A, et al. Berberine induces apoptotic cell death via activation of caspase-3 and -8 in HL-60 human leukemia cells: nuclear localization and structure-activity relationships. Am J Chin Med. 2017;45(7):1497\u2013511.","journal-title":"Am J Chin Med"},{"issue":"5","key":"402_CR23","first-page":"530","volume":"20","author":"S Mohammadi","year":"2017","unstructured":"Mohammadi S, Seyedhoseini FS, Asadi J, Yazdani Y. Effects of berberine on the secretion of cytokines and expression of genes involved in cell cycle regulation in THP-1 monocytic cell line. Iran J Basic Med Sci. 2017;20(5):530\u20137.","journal-title":"Iran J Basic Med Sci"},{"issue":"35","key":"402_CR24","doi-asserted-by":"crossref","first-page":"56811","DOI":"10.18632\/oncotarget.10796","volume":"7","author":"P Li","year":"2016","unstructured":"Li P, Diab S, Yu M, et al. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget. 2016;7(35):56811\u201325.","journal-title":"Oncotarget"},{"key":"402_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2147\/IJN.S22683","volume":"6","author":"W Tan","year":"2011","unstructured":"Tan W, Li Y, Chen M, Wang Y. Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomed. 2011;6:1773\u20137.","journal-title":"Int J Nanomed"},{"key":"402_CR26","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.2147\/IJN.S163763","volume":"13","author":"W Xiong","year":"2018","unstructured":"Xiong W, Sang W, Linghu KG, et al. Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. Int J Nanomed. 2018;13:3781\u201393.","journal-title":"Int J Nanomed"},{"issue":"1","key":"402_CR27","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1080\/10717544.2017.1410257","volume":"24","author":"YJ Li","year":"2017","unstructured":"Li YJ, Hu XB, Lu XL, et al. Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride. Drug Deliv. 2017;24(1):1868\u201373.","journal-title":"Drug Deliv"},{"issue":"3","key":"402_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ptr.2951","volume":"24","author":"IA Najar","year":"2010","unstructured":"Najar IA, Sachin BS, Sharma SC, Satti NK, Suri KA, Johri RK. Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res. 2010;24(3):454\u20138.","journal-title":"Phytother Res"},{"issue":"11","key":"402_CR29","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/ptr.2808","volume":"23","author":"W Qiu","year":"2009","unstructured":"Qiu W, Jiang XH, Liu CX, Ju Y, Jin JX. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res. 2009;23(11):1553\u20138.","journal-title":"Phytother Res"},{"key":"402_CR30","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/IJN.S127256","volume":"12","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Qian H, Yang M, et al. Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment. Int J Nanomed. 2017;12:1593\u2013605.","journal-title":"Int J Nanomed"},{"issue":"6","key":"402_CR31","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3892\/ijmm.2015.2186","volume":"35","author":"T Onodera","year":"2015","unstructured":"Onodera T, Kuriyama I, Andoh T, et al. Influence of particle size on the in vitro and in vivo anti-inflammatory and anti-allergic activities of a curcumin lipid nanoemulsion. Int J Mol Med. 2015;35(6):1720\u20138.","journal-title":"Int J Mol Med"},{"key":"402_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2017.08.004","volume":"406","author":"G Ahmad","year":"2017","unstructured":"Ahmad G, El Sadda R, Botchkina G, Ojima I, Egan J, Amiji M. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth. Cancer Lett. 2017;406:71\u201380.","journal-title":"Cancer Lett"},{"key":"402_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2217\/nnm.14.179","volume":"10","author":"YF Li","year":"2015","unstructured":"Li YF, Sun HW, Gao R, et al. Inhibited biofilm formation and improved antibacterial activity of a novel nanoemulsion against cariogenic Streptococcus mutans in vitro and in vivo. Int J Nanomed. 2015;10:447\u201362.","journal-title":"Int J Nanomed"},{"key":"402_CR34","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.2147\/IJN.S91529","volume":"10","author":"H Sun","year":"2015","unstructured":"Sun H, Wei C, Liu B, et al. Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine. Int J Nanomed. 2015;10:7275\u201390.","journal-title":"Int J Nanomed"},{"issue":"1\u20132","key":"402_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ijpharm.2012.07.008","volume":"436","author":"W Cai","year":"2012","unstructured":"Cai W, Deng W, Yang H, Chen X, Jin F. A propofol microemulsion with low free propofol in the aqueous phase: formulation, physicochemical characterization, stability and pharmacokinetics. Int J Pharm. 2012;436(1\u20132):536\u201344.","journal-title":"Int J Pharm"},{"key":"402_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/DDDT.S156123","volume":"12","author":"MUK Sahibzada","year":"2018","unstructured":"Sahibzada MUK, Sadiq A, Faidah HS, et al. Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity. Drug Des Dev Ther. 2018;12:303\u201312.","journal-title":"Drug Des Dev Ther"},{"issue":"25\u201326","key":"402_CR37","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1016\/S0264-410X(03)00381-5","volume":"21","author":"A Myc","year":"2003","unstructured":"Myc A, Kukowska-Latallo JF, Bielinska AU, et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine. 2003;21(25\u201326):3801\u201314.","journal-title":"Vaccine"},{"key":"402_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fphar.2018.00214","volume":"9","author":"R Feng","year":"2018","unstructured":"Feng R, Zhao ZX, Ma SR, Guo F, Wang Y, Jiang JD. Gut microbiota-regulated pharmacokinetics of berberine and active metabolites in beagle dogs after oral administration. Front Pharmacol. 2018;9:214.","journal-title":"Front Pharmacol"},{"issue":"9","key":"402_CR39","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","volume":"120","author":"P Ranganathan","year":"2012","unstructured":"Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765\u201373.","journal-title":"Blood"},{"issue":"24","key":"402_CR40","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Kashyap T, Yu X, et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase IIalpha to the nucleus. Clin Cancer Res. 2016;22(24):6142\u201352.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"402_CR41","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","volume":"61","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhi Y, Jin Q, et al. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)p henyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia. J Med Chem. 2018;61(4):1499\u2013518.","journal-title":"J Med Chem"},{"issue":"4","key":"402_CR42","doi-asserted-by":"publisher","first-page":"e0121730","DOI":"10.1371\/journal.pone.0121730","volume":"10","author":"C Bachas","year":"2015","unstructured":"Bachas C, Schuurhuis GJ, Zwaan CM, et al. Gene expression profiles associated with pediatric relapsed AML. PLoS ONE. 2015;10(4):e0121730.","journal-title":"PLoS ONE"},{"issue":"2","key":"402_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1532\/IJH97.05066","volume":"82","author":"H Kiyoi","year":"2005","unstructured":"Kiyoi H, Yanada M, Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol. 2005;82(2):85\u201392.","journal-title":"Int J Hematol"},{"issue":"12","key":"402_CR44","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326\u201335.","journal-title":"Blood"},{"issue":"6","key":"402_CR45","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","volume":"34","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752\u20136.","journal-title":"Leuk Res"},{"issue":"12","key":"402_CR46","doi-asserted-by":"publisher","first-page":"e0144183","DOI":"10.1371\/journal.pone.0144183","volume":"10","author":"S Wang","year":"2015","unstructured":"Wang S, Yu J, Suvira M, Setlow P, Li YQ. Uptake of and resistance to the antibiotic berberine by individual dormant, germinating and outgrowing Bacillus spores as monitored by laser tweezers Raman spectroscopy. PLoS ONE. 2015;10(12):e0144183.","journal-title":"PLoS ONE"},{"issue":"13","key":"402_CR47","doi-asserted-by":"publisher","first-page":"20909","DOI":"10.18632\/oncotarget.14959","volume":"8","author":"X La","year":"2017","unstructured":"La X, Zhang L, Li Z, Yang P, Wang Y. Berberine-induced autophagic cell death by elevating GRP78 levels in cancer cells. Oncotarget. 2017;8(13):20909\u201324.","journal-title":"Oncotarget"},{"key":"402_CR48","first-page":"1687","volume":"11","author":"R Shen","year":"2016","unstructured":"Shen R, Kim JJ, Yao M, Elbayoumi TA. Development and evaluation of vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceutical. Int J Nanomed. 2016;11:1687\u2013700.","journal-title":"Int J Nanomed"},{"issue":"4","key":"402_CR49","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s11095-014-1553-6","volume":"32","author":"S Hak","year":"2015","unstructured":"Hak S, Garaiova Z, Olsen LT, Nilsen AM, de Lange Davies C. The effects of oil-in-water nanoemulsion polyethylene glycol surface density on intracellular stability, pharmacokinetics, and biodistribution in tumor bearing mice. Pharm Res. 2015;32(4):1475\u201385.","journal-title":"Pharm Res"},{"issue":"10","key":"402_CR50","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.3390\/ijerph111010016","volume":"11","author":"E Winter","year":"2014","unstructured":"Winter E, Pizzol CD, Locatelli C, et al. In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: insights and challenges in targeted cancer chemotherapies. Int J Environ Res Public Health. 2014;11(10):10016\u201335.","journal-title":"Int J Environ Res Public Health"},{"key":"402_CR51","first-page":"239749","volume":"2015","author":"Z Wang","year":"2015","unstructured":"Wang Z, Wu J, Zhou Q, Wang Y, Chen T. Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL\/6 mice. Evid Based Complement Alternat Med. 2015;2015:239749.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"402_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.apsb.2016.01.006","volume":"6","author":"L Chen","year":"2016","unstructured":"Chen L, Lu X, Liang X, et al. Mechanistic studies of the transport of peimine in the Caco-2 cell model. Acta Pharm Sin B. 2016;6(2):125\u201331.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"402_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.abb.2012.06.004","volume":"527","author":"JM Planas","year":"2012","unstructured":"Planas JM, Alfaras I, Colom H, Juan ME. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys. 2012;527(2):67\u201373.","journal-title":"Arch Biochem Biophys"},{"key":"402_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.leukres.2017.05.004","volume":"58","author":"A Gopalakrishnapillai","year":"2017","unstructured":"Gopalakrishnapillai A, Kolb EA, McCahan SM, Barwe SP. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Leuk Res. 2017;58:91\u20137.","journal-title":"Leuk Res"},{"issue":"14","key":"402_CR55","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-05-0358","volume":"11","author":"DE Lopes de Menezes","year":"2005","unstructured":"Lopes de Menezes DE, Peng J, Garrett EN, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res. 2005;11(14):5281\u201391.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"402_CR56","first-page":"407","volume":"21","author":"FS Yu","year":"2007","unstructured":"Yu FS, Yang JS, Lin HJ, et al. Berberine inhibits WEHI-3 leukemia cells in vivo. In Vivo. 2007;21(2):407\u201312.","journal-title":"In Vivo"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-018-0402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12951-018-0402-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-018-0402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T02:33:12Z","timestamp":1605148392000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-018-0402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/s12951-018-0402-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]},"assertion":[{"value":"10 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"76"}}